Standard therapy for glioblastoma--a review of where we are.
about
Characterization of a novel anti-cancer compound for astrocytomasAdvances in epigenetic glioblastoma therapy.Subgroup economic analysis for glioblastoma in a health resource-limited setting.Intracranial hyperthermia through local photothermal heating with a fiberoptic microneedle device.Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.All-trans retinoic acid inhibits migration, invasion and proliferation, and promotes apoptosis in glioma cells in vitro.In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog modelTumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas.From patient-specific mathematical neuro-oncology to precision medicineBACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.Molecular targets in glioblastoma.Apoptosis-inducing effects of Melissa officinalis L. essential oil in glioblastoma multiforme cells.Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway.Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?Cytotoxic profiling of artesunic and betulinic acids and their synthetic hybrid compound on neurons and gliomas.Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma.A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.Chronic arterial hypertension impedes glioma growth: a multiparametric MRI study in the rat.MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.Hypoxia upregulates aldehyde dehydrogenase isoform 1 (ALDH1) expression and induces functional stem cell characteristics in human glioblastoma cells.Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase.Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis
P2860
Q28543237-3E635A46-89CC-4BE3-B0A2-62721FE9BB64Q33567030-C5EF446D-047E-40BB-B3D5-B415068C56FFQ34236812-FB0FE575-7C7D-4209-97B6-AFF39AB3EBCDQ34579762-180EF91F-B66E-4C6A-8BDD-53DD6A8D17F9Q35222941-6F5A21A4-C8B3-4B3C-9F40-5637D5914607Q35759006-813A1878-3C53-46A3-9173-AF537513986FQ36303065-C31993A9-4C3C-4931-A27F-7AFD3F1BEB6DQ36651893-55FB52A5-AC78-490B-93D3-3FF58CB638F0Q36733380-D4065940-7BC3-457D-A812-867F2AE25F23Q37522376-010C3695-FFC8-4A5B-89BA-BC3F6DEB6534Q38179019-894628AD-563D-4FC9-AB44-AE7D8BC8139AQ38465854-12AA12A1-8CE6-4AE2-A345-DCAC1D930FDDQ39003039-E2118FFD-85FC-40A8-A0F0-361F8D6D7ABCQ39096529-E2FE7933-A212-418B-9D0E-72CD4579027CQ39512205-0FC018BC-25F0-476F-A15E-C30F26F7FF29Q39711507-630170D0-8FD3-47A5-B177-3B7A779C81C1Q41845885-478D243F-2E13-4422-8780-8BCFD2EB6EB8Q42008851-94B8163F-E4C1-4BD3-8A87-551070B98A70Q44501507-B8AF4AC1-1CE3-4016-B0AC-327DF405C0B2Q48124224-CC3D70C5-5CBB-4E25-9378-A872349FBC26Q48873373-C07962DA-3490-4BD3-BDCA-A308D9C8AEDCQ48889888-BBF9194B-DA96-4555-9410-EBC6A186BCBCQ55463316-954E9E8E-7095-4C97-8BDC-7392708492A5Q55517828-438AF9EA-0782-46A2-B855-AC9BF150FCF5Q58755619-8D478D18-F6F9-417E-8CA1-BCA2965F1FF6
P2860
Standard therapy for glioblastoma--a review of where we are.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Standard therapy for glioblastoma--a review of where we are.
@ast
Standard therapy for glioblastoma--a review of where we are.
@en
Standard therapy for glioblastoma--a review of where we are.
@nl
type
label
Standard therapy for glioblastoma--a review of where we are.
@ast
Standard therapy for glioblastoma--a review of where we are.
@en
Standard therapy for glioblastoma--a review of where we are.
@nl
prefLabel
Standard therapy for glioblastoma--a review of where we are.
@ast
Standard therapy for glioblastoma--a review of where we are.
@en
Standard therapy for glioblastoma--a review of where we are.
@nl
P356
P1476
Standard therapy for glioblastoma--a review of where we are.
@en
P2093
Ryo Nishikawa
P304
P356
10.2176/NMC.50.713
P577
2010-01-01T00:00:00Z